EMA Information Day on Measuring the Impact of Pharmacovigilance Activities

How to measure pharmacovigilance activities to be effective and efficient? At this EMA Info Day you will learn about the revised PRAC strategy for measuring the effectiveness of the EU pharmacovigilance activities.

Back to Agenda

SESSION 1: THE REGULATORY FRAMEWORK FOR IMPACT EVALUATION OF PHARMACOVIGILANCE ACTIVITIES

Session Chair(s)

Marieke De Bruin, PHARMD, PHD

Scientific Director, Utrecht Collaborating Centre for Pharmaceutical Policy and Regulation, Netherlands

Kaisa Immonen

Director of Policy , European Patients' Forum, Belgium

This session will provide an overview of the updated framework for the evaluation of the impact of regulatory decisions in pharmacovigilance based on workshop recommendations and practical experience.

Speaker(s)

Revised PRAC Strategy for measuring impact of regulatory decisions

Chief Executive, Medicines and Healthcare Products Regulatory Agency (MHRA), United Kingdom

Impact evaluation of pharmacovigilance activities – industry perspective

Vice President, Pharmacovigilance Excellence and International QPPV, Abbvie, United Kingdom

A conceptual framework for the evaluation of effectiveness of risk minimisation: Experience at the Danish Medicines Agency

Senior Advisor, Data Analytics Centre, Danish Medicines Agency, Denmark

Have an account?